Key result
Once-daily telmisartan 40-80 mg for 24 weeks achieved target blood pressure in 69.6% of patients and reduced left ventricular mass index from 151.6 to 135.1 g/m2.
Why the study?
Does telmisartan reduce blood pressure and left ventricular mass index in patients with mild-to-moderate hypertension and left ventricular hypertrophy?
Population
24 patients with mild-to-moderate hypertension and left ventricular hypertrophy (LVH)
Design
Cohort, open-label
Follow-up
24 weeks
Authors
Loading...
May support telmisartan for BP control with LVH regression; hypothesis-generating and requires RCTs before practice change.
Does telmisartan reduce blood pressure and left ventricular mass index in patients with mild-to-moderate hypertension and left ventricular hypertrophy?
Telmisartan effectively reduces blood pressure and induces regression of left ventricular hypertrophy in patients with mild-to-moderate hypertension.
Ivanova et al. (2005) studied Mild-to-moderate hypertension and left ventricular hypertrophy (n=24). Telmisartan was evaluated on Target blood pressure levels (SBP/DBP < 140/90 mm Hg). Once-daily telmisartan 40-80 mg for 24 weeks achieved target blood pressure in 69.6% of patients and reduced left ventricular mass index from 151.6 to 135.1 g/m2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: